Njunda, Nsagha, Assob, Palle, Kamga, Nde, Ntube, and Weledji: Genital mycoplasmas in women attending the Yaoundé University Teaching Hospital in Cameroon

Genital mycoplasmas in women attending the Yaoundé University Teaching Hospital in Cameroon

Abstract

Genital mycoplasmas are implicated in pelvic inflammatory diseases, puerperal infection, septic abortions, low birth weight, nongonococcal urethritis and prostatitis as well as spontaneous abortion and infertility in women. There is paucity of data on colonisation of genital mycoplasma in women and their drug sensitivity patterns. The aim of our study was to determine the prevalence of genital mycoplasmas (Ureaplasma urealiticum and Mycoplasma hominis) infection and their drug sensitivity patterns in women. A mycofast kit was used for biochemical determination of mycoplasma infection in 100 randomly selected female patients aged 19–57 years, attending the University of Yaoundé Teaching Hospital (UYTH) from March to June 2010. Informed consent was sought and gained before samples were collected. Genital mycoplasmas were found in 65 patients (65%) [95% CI=55.7–74.3%] and distributed as 41 (41%) [95% CI=31.4–50.6%] for U. urealiticum and 4 (4%) [95% CI=0.20– 7.8%] for M. hominis while there was co-infection in 20 women (20%) [95% CI=12.16–27.84%]. In our study, 57 (57%) [95% CI=47.3–67%] had other organisms, which included C. albicans (19 [19%]), G. vaginalis (35 [35%]) and T. vaginalis (3 [3%]). Among the 65 women with genital mycoplasma, the highest co-infection was with G. vaginalis (33.8%). Pristinamycine was the most effective antibiotic (92%) and sulfamethoxazole the most resistant (8%) antibiotic to genital mycoplasmas. We conclude that genital mycoplasma is a problem in Cameroon and infected women should be treated together with their partners.





Introduction

Mycoplasmas are the smallest known free-living organisms with a size between 150 and 250 nm. They are fungi-like in nature, hence the prefix myco-, and lack a cell wall, hence the suffix -plasma. Mycoplasma refers to the plasticity of bacterial forms resembling fungal elements. The absence of a cell wall in mycoplasmas is responsible for the lack of a Gram stain reaction and non-susceptibility to most antimicrobials including beta-lactams, which act on cell walls. They inhabit mucous membranes as in the genital and respiratory tracts.1 Mycoplasmas were first thought to be viruses because they passed through filters that retain bacteria. It was discovered later that they had bacterial properties (both DNA and RNA and they could grow in cell-free media). They differ from L-form bacteria in that they have sterols in their cell membranes.2 Genital mycoplasmas have been implicated in pelvic inflammatory diseases, puerperal infection, septic abortions, low birth weight, nongonococcal urethritis and prostatitis as well as spontaneous abortion and infertility.3 Mycoplasmas are also known to be part of the commensal flora of the genitourinary tract mucosa and are found in the majority of sexually active humans.4,5 Mycoplasma genitalium has become the third most frequent pathogen causing nongonococcal urethritis.6 It has also been reported that Mycoplasma hominis is a cofactor for bacterial vaginosis and pelvic inflammatory disease.6 Gdoura et al.,7 in a study conducted in Tunisia, have shown a high prevalence of M. hominis.

Our study investigated the genital mycoplasma species M. homonis and Ureaplasma urealiticum and their drug sensitivity patterns. These microorganisms are cultured as compared to other mycolasmas, which are fastidious and cannot be cultured but can only be studied using the PCR method.8 Our study also investigated the relationship between genital mycoplasma infection and Candida albicans, Gadnerella vaginalis and Trichomonas vaginalis. We report here the prevalence of genital mycoplasmas in women attending the University of Yaoundé Teaching Hospital, their drug sensitivity pattern and the relationship between genital mycoplasmas and C. albicans, G. vaginalis and T. vaginalis.

Materials and Methods

Study site

Our study was carried out in the bacteriology laboratory of the University of Yaoundé Teaching Hospital. The study participants were inhabitants of Yaoundé and its environs. Yaoundé is the capital of Cameroon and is made up of inhabitants from all parts of the country as it is a metropolitan city.

Design and sampling procedures

The design was a cross-sectional one. Sexually active women, both pregnant and non-pregnant, were randomly selected for the study. This study was conducted between March 1 and June 30, 2010. The sample size consisted of patients who attended the University of Yaoundé Teaching Hospital for different obstetric and gynaecological problems. Women who were menstruating, who did douching (vaginal washing) and virgins were all excluded. The patients were educated on the advantages of performing this test and informed consent was sought and gained before samples were collected. If the patient decided to do the test, we proceeded with collection of high vaginal swabs.

Laboratory procedures

Mycofast Evolution 3 Culture Media

Mycofast Evolution 3 Media (BioMerieux) permit the detection, quantification and identification of M. hominis and U. urealiticum from endocervical, urinary and gastric specimens and in spermatozoa. It also gives the sensitivity of these organisms to different antibiotics. Mycofast Evolution 3 Culture Media is a liquid method based on the ability of M. hominis and U. urealiticum to metabolise urea and arginine, respectively. The presence of genital mycoplasmas is indicated by a change in colour with the aid of phenol red. This changes the colour of the media from yellow to orange or red owing to the release of ammonia. The reagents used included U.M.M.t: containing transport media for mycoplasma; U.M.M.lyo: with lyophilised media for growth; Galerie Mycofast Evolution 3: containing 20 wells; S.M.h: Mycoplasma hominis activator (4.5 mL).

Inoculation on media

All reagents were allowed to attain room temperature for 20–30 minutes. The swab was placed in U.M.M.t and mixed. The U.M.M.lyo was regenerated with the entire content of the U.M.M.t medium. Half a millilitre of the latter was transferred into the empty U.M.M.t vial and incubated for 24–48 hours at 37°C. A yellow colouration is negative while a red/orange screen is a positive result. The remaining 2.5 mL of inoculated U.M.M.lyo medium that was stored at 2–8°C was used to continue the procedure for positive results. The diagnosis of the species was confirmed with the Mycofast Evolution Tray 3 and S.M.h. An antibiotic susceptibility test was carried out for each species and read as intermediate, sensitive or resistant.

T. vaginalis was identified using wet preparations. Gram smears of genital specimens were carried out. The specimens were inoculated aseptically on sabouraud supplemented with 5% chloramphenicol agar plates. Plates were incubated at temperatures of 37°C for 24 hours, after which they were examined for colonial characteristics and their identity confirmed and characterised by the following tests: germ tube and biochemical kit analytic profile index (API 20E) for C. albicans and G. vaginalis.

Data management and analysis

Each patient's demographic profile including laboratory results were entered on structured forms for all clinic days during the study period. The information was verified every week for the use of correct codes and consistency checks. Data were entered into Microsoft Excel sheets and exported to Epi-Info for analysis using descriptive statistics. Statistical significance was set at 95%.

At the initial step of the analyses, frequency distributions of each variable were produced and the information arranged according to age groups and sensitivity patterns. Associations were established between variables of different measures through cross-tabulations. Further analysis included a data summary including proportions, percentages and standard deviations. In these analyses, such methods as the χ2 test, Fisher exact test for the test of significance of associations between categorical variables, and the student-t test to test statistical significance of hypotheses for continuous variables were used.

Results

Prevalence of genital mycoplasmas among the different age groups

We studied 100 female patients ranging between the ages of 19 and 57 years. Table 1 shows that genital mycoplasmas were detected in 65 women (65%) [95% CI=55.7–74.3%], 41% [95% CI=31.4–50.6%] had U. urealiticum, 4% [95% CI=0.20–7.8%] had M. hominis and 20% [95% CI=12.16–27.84%] had mixed infection. Mycoplasma infection was highest in the 25–29 year group (16%) [95% CI=15.7–16.3%].

Table 1

Prevalence of genital mycoplasmas in the different age groups.

Age range
(yr)
Total patients
No (%)
Mycoplasma hominis
(MH) only
No (%)
Ureaplasma urealiticum
(UU) only
No (%)
Mixed infection
(MHUU)
No (%)
Total
No (%)
1519 2 (2) 0 (0) 1 (1) 1 (1) 2 (2)
2024 18 (18) 2 (2) 6 (6) 4 (4) 12 (12)
2529 24 (24) 1 (1) 11 (11) 4 (4) 16 (16)
3034 18 (18) 1 (1) 5 (5) 4 (4) 10 (10)
3539 10 (10) 0 (0) 8 (8) 0 (0) 8 (8)
4044 13 (13) 0 (0) 4 (4) 3 (3) 7 (7)
4549 10 (10) 0 (0) 3 (3) 3 (3) 6 (6)
5054 4 (4) 0 (0) 3 (3) 1 (1) 4 (4)
5559 1 (1) 0 (0) 0 (0) 0 (0) 0 (0)
Total 100 4 (4) 41 (41) 20 (20) 65 (65)

Interaction between genital mycoplasmas and other pathogens

Out of the 100 female patients who were examined for genital mycoplasmas, 57 (57%) [95% CI=47.3–67%] had other pathogens, which included C. albicans (19 [19%]), G. vaginalis (35 [35%]) and T. vaginalis (3 [3%]). Of the 65 women who had genital mycoplasmas, 36 (55.4%) harboured these other pathogens. These included mainly G. vaginalis (22 [33.8%]) followed by C. albicans (12 [18.5%]) and T. vaginalis (2 [3.1%]). There was a 63.3% interaction of these organisms with genital mycoplasma. There was no significant difference in the rate of interaction with the different pathogens (P>0.5) (Table 2).

Table 2

Reltionship between genital mycoplasmas and Candida albicans, Gadneralla vaginalis and Trichomonas vaginalis.

Microorganisms Number
examined
n=100
No (%)
Co-infection with
genital mycoplasma
n=65
No (%)
Percentage interaction
of these pathogens
with genital mycoplasmas
Candida albicans 19 (19) 12 (18.5) 63.2
Gadnerella vaginalis 35 (35) 22 (33.8) 62.9
Trichomonas vaginalis 3 (3) 2 (3.1) 66.7
Total 57 (57) 36 (55.4) 63.2

Assessment of antibiotics against genital mycolasmas

The mycofast kit for mycoplasma also contained wells for different antibiotics, which included lincomycine, trimethoprim-sulfamethoxazole, erythromycin, doxycycline, pristinamycine, ciprofloxacin, ofloxacine, josamycine, azithromycin and roxithromycin.

Antibiotic susceptibility of M. hominis, U. urealiticum and co-infection were determined. U. urealiticum was very sensitive to erythromycin, pristinamycine and josamycine and least sensitive to lincomycine and ciprofloxacin. M. hominis was most sensitive to lincomycine, doxycycline, pristinamycine and josamycine and least sensitive to sulfamethoxazole, erythromycine, roxithromycine and azithromycin (Table 3). The most sensitive antibiotic to genital mycoplasmas was pristinamycine (92%) while the least sensitive was trimetropine-sulfamethoxazole (8%) (Table 4).

Table 3

Antibiotic sensitivity of genital mycoplasmas isolated.

Antibiotics General sensitivity UU MH UU and MH
S I R S I R S I R S I R
n=65 n=41 n=4 n=20
Lincomycine 7 2 56 2 2 37 3 0 1 2 0 18
Trimethoprim-
sulfamethoxazole
5 1 59 2 1 38 0 0 4 3 0 17
Erythromycin 41 1 23 40 1 0 0 0 4 1 10 19
Doxycycline 44 0 21 24 0 17 4 0 0 16 0 4
Pristinamycine 60 1 4 40 1 0 4 0 0 16 0 4
Roxithromycine 31 14 20 29 12 0 0 1 3 2 1 17
Azithromycine 43 2 20 29 12 0 0 1 3 3 0 17
Josamycine 49 4 12 41 0 0 4 0 0 4 4 12
Ciprofloxacin 8 9 48 4 5 31 2 1 1 2 2 16
Ofloxacine 7 48 10 3 34 4 1 2 1 3 12 5

[i] S,sensitive; I, intermediate; R, resistant.

Table 4

Antibiotic sensitivity to genital mycoplasmas isolated.

PT JM DO AZM E ROX CIP OFX L SXT
MHUUcoinfection 60 49 44 43 41 32 8 7 7 5
Percentage (%) 92 75 68 66 63 49 12 10 10 8
PT>JM>DO>AZM>E>ROX>CIP>OFX>L>SXT

[i] PT, pristinamycine; JM, josamycine; DO, oxycycline; AZM, azithromycin; E, erythromycin; ROX, roxithromycin; CIP, ciprofloxacin; OFX, ofloxacine; L, lincomycine; SXT, trimethoprim-sulfamethoxazole.

Discussion

Out of the 100 women, 65 were positive for genital mycoplasmas, giving a prevalence of 65% with 4% for M. hominis, 41% for U. urealiticum and a co-infection of 20%. Mixed infection is owing to the fact that both pathogens survive better in alkaline pH.9 This is a little higher than results obtained by Elias et al.10 who, in a group of 222 women in a similar age range, found U. urealiticum in 31.8% and M. hominis in only 3% of the cases. Schlicht et al.11 found a higher prevalence of 54% for U. urealiticum. Agbakoba and associates9 found a prevalence of 36.7% for genital mycoplasmas while working with Nigerian women. Zdrodowska-Stefanow et al.,12 in a similar study in women presenting with urogenital diseases, showed that U. urealyticum was detected in 161 (29.8%) and M. hominis in 20 (3.7%) women. In this study, the fact that the highest percentage of mycoplasma-positive cultures was found in patients of the STD clinic and in infertile women confirms the fact that mycoplasmas play an important role in the aetiopathogenesis of inflammatory states of the genitourinary organs. It was also observed that genital mycoplasma infection is not specific to any age group but that with the highest prevalence is the 25–30 year group with 16%. It is related to sexual activity, hence any sexually active group is a potential carrier. A similar result was obtained by Zdrodowska-Stefanow et al.,12 with the highest rate in the age range of 26–30 years (29.2% for U. urealyticum and 50.0% for M. hominis).

Among the women in our study, 57% had other pathogens including C. albicans (19%), G. vaginalis (35%) and T. vaginalis (3%). Thirty-six (55.4%) of these pathogens were co-infected with genital mycoplasma, the most prevalent pathogen being G. vaginalis (33.8%). This falls in line with the conclusion made by Paavonen et al.13 and Shafer et al.,14 who have revealed that genital mycoplasma is detected significantly more often in women with bacterial vaginosis than in those without. These results are higher than those reported by Agbakoba et al.15 who, while working with 168 women, found that 76 (42.5%) were infected with other organisms, which included C. albicans (16.7%), G. vaginalis (11.9%) and T. vaginalis (3.4%). The high prevalence of co-infection of mycoplasma with candidiasis opposes the findings of Koch et al.,16 who reported that mycoplasmas occur less frequently with genital candidiasis. Agbakoba and associates9 supported Koch and colleagues16 by saying that mycoplasmas thrive better in near alkaline pH but candida lowers the vaginal pH. The high prevalence of G. vaginalis is owing to the fact that it is one of the main causes of bacterial vaginosis.17 All these isolates may play various interactive roles in the urogenital tract of women, which could lead to various adverse conditions in the long run, hence should not be neglected. The 63.2% colonisation with C. albicans, G. vaginalis or T. vaginalis shows that patients diagnosed with any of these infections have an increased chance of infection with genital mycoplasmas.

Regarding antibiotic susceptibility, pristina-mycine was the most sensitive (with 92% sensitivity) and trimetroprine-sulfamethoxazole the most resistant (with 8% sensitivity). The drug of choice between 1983 and 1984 was tetracycline and the alternative drug was erythromycin.1 The high sensitivity of U. urealiticum to erythromycine and doxycycline with resistance to lincomycine was observed by Jafar and colleagues.18 The latter also observed that M. hominis was sensitive to lincomycine and doxycycline, as found in this study. Presently, both M. hominis and ureaplasma strains are highly resistant to tetracycline.18 Ryan et al.19 have revealed that sexually transmitted diseases are common among sex workers in Cameroon. It is therefore important that erythromycin be administered to patients presenting with symptoms of non-chlamydial, non-gonococcal uretrithis, as recommended by Jenkins20 because, in most areas in developing countries, laboratories facilities are rare. This is confirmed by our results showing that about 63% of the isolates were sensitive to this antibiotic.

Conclusions

Genital mycoplasma is a problem in Cameroon and infected women should be treated together with their partners. The incidence of U. urealyticum and M. hominis infections of the female genitourinary system is distinctly correlated with age and sexual activity. The diagnosis of the inflammatory states of the genitourinary system and their complications should involve tests for these pathogens, especially for U. urealyticum. Pristinamycine was the most effective antibiotic (92%) and sulfamethoxazole the most resistant (8%) antibiotic to genital mycoplasmas.

References

1 

E JawetzJL MelnickEA AdelbergReview of Medical Microbiology16th ed.OxfordLange Medical Publications19842846

2 

C ArchanaC O'KeefeMycoplasma infections2010Available from: emedicine.medscape.com/article/966785

3 

J FribergDiagnosis of genital mycoplasma and ureaplasma infectionsJ Reprod Med198530S25861

4 

P LeszczyńskiR SzymańskiMykoplazmy w zakaeniach poło-niczo-ginekologicznychNowa Medycyna19987257

5 

KT NiemiecZakaenia Wywołane przez mykoplazmy urogenitalneKlin Perinat Gin2003372933

6 

M HartmannGenital mycoplasmaDtsch Dermatol Ges200973717

7 

R GdouraW KchaouL Ammar-KeskesAssessment of Chamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis, and Mycoplasma genitalium in semen and first void urine specimens of asystematic male partners of infertile couplesJ Androl200829198206

8 

BW KenUreaplasma infection2009Available from: emedicine.medscape.com/ article/231470

9 

NR AgbakobaPrevalence of mycoplasma and ureaplasma in women attending gynaecology clinic at University College Hospital, Ibadan and pathogenicity of Ureaplasma urealiticum in mice2007Ph.D thesisUniversity of Ibadan Nigeria

10 

M EliasJ GrześkoR SiejkowskiObecność Mycoplasma hominis i Ureaplasma urealyticum w kanale szyjki macicy kobietGin Pol2005762832

11 

MJ SchlichtSD LovrichJS SartinHigh prevalence of genital mycoplasmas among sexually active young adults with urethritis or cervicitis symptoms in La Crosse, WinconsinJ Clin Microbiol200442463640

12 

B Zdrodowska-StefanowWM KłosowskaI Ostaszewska-PuchalskaUreaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseasesAdv Med Sci2006512504

13 

J PaavonenA MiettinenCE StevensMycoplasma hominis in nonspecific vaginitisSex Transm Dis1983102715

14 

MA ShaferRL SweetMJ Ohm-SmithMicrobiology of the lower genital tract in postmenarchal adolescent girls: differences by sexual activity, contraception, and presence of nonspecific vaginitisJ Pediatrics198510797481

15 

NR AgbakobaAI AdetosoyeIF AdewoleCM ChukwumaIsolation of vaginal pathogens along with genital mycoplasmas from asymptomatic gynaecology and antenatal clinic attendeesAmerican-Eurasian J Sci Res200831958

16 

AA KochA BilinaD TcodorowiczA StaryMycoplasma hominis and Ureaplasma urealyticum in patients with sexually transmitted diseasesWien Klin Wochenschr19971095849

17 

GG DondersB Van-BulkJ CandronRelationship of bacterial vaginosis and mycoplasmas to the risk of spontaneous abortionAm J Obstet Gynaecol20001834317

18 

J. KhanR. FarzandPB. GhumroAntibiotic sensitivity of human genital mycoplasmasAfr J Microbiol Res201047407

19 

KA RyanL ZekengRE RoddySS WeirPrevalence and prediction of sexually transmitted diseases among sex workers in CameroonInt J STD AIDS199894037

20 

S JenkinsChlamydia, mycoplasma and rikettsiaIn Clinical Laboratory MedicineBaltimoreLippincott Williams and Wilkins200411958

Abstract views:
772

Views:
PDF
198
HTML
1162

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM




Copyright (c) 2011 Anna L. Njunda, Dickson S. Nsagha, Jules C.N. Assob, John N. Palle, Henri L. Kamga, Peter F. Nde, Mengang N.C. Ntube, Patrick E. Weledji

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185